Literature DB >> 10545789

IL-6, M-CSF and IAP cytokines in ovarian cancer: simultaneous assessment of serum levels.

E Foti1, G Ferrandina, R Martucci, M E Romanini, P Benedetti Panici, U Testa, S Mancuso, G Scambia.   

Abstract

The aim of this study was to simultaneously determine IL-6, M-CSF and IAP levels in 61 serum samples of previously untreated ovarian cancer patients. A direct correlation between IL-6 and M-CSF has been found in our patient population (r = +0.41, p = 0.013), while IAP serum levels failed to correlate with M-CSF (r = +0.15, p = 0. 24) and IL-6 (r = +0.17, p = 0.18) levels. Since IL-6 and M-CSF have been demonstrated to be both induced in response to the same agents, it is conceivable that a mechanism of coregulation in the production of these cytokines by tumor cells and macrophages might occur. The direct correlation between IL-6 and M-CSF also suggests that tumor-derived cytokines can potentially lead to a self-maintaining cytokine network by recruiting cytokine-producing host cells and by perpetuating cytokine production.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10545789     DOI: 10.1159/000012033

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  4 in total

1.  Consistent interactions between tumor cell IL-6 and macrophage TNF-α enhance the growth of human prostate cancer cells in the bone of nude mouse.

Authors:  Seung Wook Kim; Jang Seong Kim; John Papadopoulos; Hyun Jin Choi; Junqin He; Marva Maya; Robert R Langley; Dominic Fan; Isaiah J Fidler; Sun-Jin Kim
Journal:  Int Immunopharmacol       Date:  2011-01-18       Impact factor: 4.932

Review 2.  Myeloid-derived suppressor cells: the dark knight or the joker in viral infections?

Authors:  Celeste Goh; Sowmya Narayanan; Young S Hahn
Journal:  Immunol Rev       Date:  2013-09       Impact factor: 12.988

3.  Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash.

Authors:  Russell J Schilder; Harsh B Pathak; Anna E Lokshin; Robert W Holloway; Ronald D Alvarez; Carol Aghajanian; Hua Min; Karthik Devarajan; Eric Ross; Charles W Drescher; Andrew K Godwin
Journal:  Gynecol Oncol       Date:  2009-01-21       Impact factor: 5.482

Review 4.  The Role of Myeloid-Derived Suppressor Cells in Viral Infection.

Authors:  Megan A O'Connor; Jessica L Rastad; William R Green
Journal:  Viral Immunol       Date:  2017-01-04       Impact factor: 2.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.